Literature DB >> 11134376

Can emergency department physicians safely and effectively initiate thrombolysis for acute ischemic stroke?

P T Akins1, C Delemos, D Wentworth, J Byer, S J Schorer, R P Atkinson.   

Abstract

OBJECTIVE: To review the clinical outcomes of stroke patients treated with IV tissue plasminogen activator (tPA; alteplase) in a community setting and to compare outcomes when treatment was initiated by a neurologist or an emergency department (ED) physician in telephone consultation with a neurologist and radiologist.
METHODS: Clinical information was prospectively collected for 43 stroke patients treated with IV tPA (alteplase) within a five-hospital network of affiliated community hospitals. Blinded 3-month outcomes were obtained with telephone interview or patient visit.
RESULTS: Excellent functional recovery measured by a Modified Rankin score of 0 to 1 (42%), symptomatic intracerebral hemorrhages (7%), and mortality (16.3%) were similar to those reported by National Institute of Neurological Disorders and Stroke (39%, 7.7%, 17.3%). After initial screening by an ED physician, 20 patients were directly examined by a stroke neurologist who then prescribed tPA. Twenty-three patients received tPA prescribed by an ED physician after telephone consultation with a neurologist and review of the head CT by a radiologist. Functional outcome, symptomatic intracerebral bleeding rate, and mortality rate were similar between these groups. Door-to-needle time was similar. Protocol deviations were much higher when ED physicians prescribed the tPA compared to when neurologists did (30% versus 5%). These protocol deviations were reduced with staff education.
CONCLUSIONS: The clinical results of the National Institute of Neurological Disorders and Stroke tPA Stroke Trial were replicated in this small series of patients treated in a community setting. Outcomes were similar whether the prescribing physician was a neurologist or an ED physician.

Entities:  

Mesh:

Year:  2000        PMID: 11134376     DOI: 10.1212/wnl.55.12.1801

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

1.  Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Maarten G Lansberg; Martin J O'Donnell; Pooja Khatri; Eddy S Lang; Mai N Nguyen-Huynh; Neil E Schwartz; Frank A Sonnenberg; Sam Schulman; Per Olav Vandvik; Frederick A Spencer; Pablo Alonso-Coello; Gordon H Guyatt; Elie A Akl
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.

Authors:  Phillip A Scott; Shirley M Frederiksen; John D Kalbfleisch; Zhenzhen Xu; William J Meurer; Angela F Caveney; Annette Sandretto; Ann B Holden; Mary N Haan; Ellen G Hoeffner; Sameer A Ansari; David P Lambert; Michael Jaggi; William G Barsan; Robert Silbergleit
Journal:  Acad Emerg Med       Date:  2010-10       Impact factor: 3.451

Review 3.  From the inside looking out: a view from the fishbowl.

Authors:  J Stephen Huff; Jonathan A Edlow; Scott Silvers
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

4.  Remote supervision of IV-tPA for acute ischemic stroke by telemedicine or telephone before transfer to a regional stroke center is feasible and safe.

Authors:  Muhammad A Pervez; Gisele Silva; Shihab Masrur; Rebecca A Betensky; Karen L Furie; Renzo Hidalgo; Fabricio Lima; Eric S Rosenthal; Natalia Rost; Anand Viswanathan; Lee H Schwamm
Journal:  Stroke       Date:  2009-11-12       Impact factor: 7.914

5.  Tissue Plasminogen Activator Prescription and Administration Errors within a Regional Stroke System.

Authors:  Lee S Chung; Aleksander Tkach; Erin M Lingenfelter; Sarah B Dehoney; Jeannie Rollo; Adam de Havenon; L Dana DeWitt; Matthew R Grantz; Haimei Wang; Jana J Wold; Peter M Hannon; Natalie R Weathered; Jennifer J Majersik
Journal:  J Stroke Cerebrovasc Dis       Date:  2015-12-11       Impact factor: 2.136

Review 6.  Controversies about tissue plasminogen activator: extending the window of therapy.

Authors:  S C Orr; C R Gomez
Journal:  Curr Atheroscler Rep       Date:  2001-07       Impact factor: 5.113

Review 7.  Imaging-guided acute ischemic stroke therapy: From "time is brain" to "physiology is brain".

Authors:  R G González
Journal:  AJNR Am J Neuroradiol       Date:  2006-04       Impact factor: 3.825

8.  Protocol Deviations before and after Treatment with Intravenous Tissue Plasminogen Activator in Community Hospitals.

Authors:  Eric E Adelman; Phillip A Scott; Lesli E Skolarus; Allison K Fox; Shirley M Frederiksen; William J Meurer
Journal:  J Stroke Cerebrovasc Dis       Date:  2015-09-26       Impact factor: 2.136

9.  Contemporary Approaches to the Management of Neurosurgical Complications of Infective Endocarditis.

Authors:  Alan R. Turtz; Steven S. Yocom
Journal:  Curr Infect Dis Rep       Date:  2001-08       Impact factor: 3.663

10.  Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: feasibility and effectivity from an Indian perspective.

Authors:  S R Sharma; Nalini Sharma
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.